SCHEMBL26100377

SCHEMBL26100377

O=C(Nc1cccc(Cl)c1)c1c2c(nc3ccc(Cl)cc13)CCN(CCc1ccccc1)C2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.55
▸ GAA P10253 2/20 0.55
▸ MAPT P10636 6/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ TP53 P04637 3/20 0.49
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ HTT P42858 2/20 0.48
▸ ALDH1A1 P00352 8/20 0.47
▸ POLB P06746 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ PRMT5 O14744 1/20 0.46
▸ WDR77 Q9BQA1 1/20 0.46
▸ USP7 Q93009 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.44
▸ TSHR P16473 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26099566 0.94 LMNA (0.56) LMNAGAAMAPTSMN1; SMN2TP53
SCHEMBL26099622 0.93 MAPT (0.56) LMNAGAAMAPTSMN1; SMN2TP53
SCHEMBL26097544 0.91 MAPT (0.50) LMNAGAAMAPTSMN1; SMN2TP53
SCHEMBL26098741 0.90 MAPT (0.53) LMNAGAAMAPTSMN1; SMN2TP53
SCHEMBL26097289 0.88 MAPT (0.54) LMNAGAAMAPTSMN1; SMN2TP53
SCHEMBL26097193 0.87 MAPT (0.57) LMNAGAAMAPTSMN1; SMN2TP53
SCHEMBL31666080 0.86 TDP1 (0.56) LMNAMAPTSMN1; SMN2TP53NPC1
SCHEMBL26100476 0.86 TDP1 (0.56) LMNAMAPTSMN1; SMN2TP53NPC1
SCHEMBL26098861 0.85 MAPT (0.51) LMNAGAAMAPTSMN1; SMN2TP53
SCHEMBL26454732 0.84 MAPT (0.68) LMNAGAAMAPTSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12370183-B2 Compositions and methods for treating malaria RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-07-29 — — US disclosed
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-05-04 — — US disclosed
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-05-04 — — US disclosed
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12370183-B2 Compositions and methods for treating malaria G6PD, QDPR, FASN LMNA 969/4885GAA 269/4885MAPT 1034/4885
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA G6PD, QDPR, FASN LMNA 969/4885GAA 269/4885MAPT 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback